Personalis Inc Equity-NMS: PSNL

Healthcare

Diagnostics & Research

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$3.51
Open :	$3.49
Today's high :	$3.65
Today's low :	$3.4
52W low :	$1.135
52W high :	$7.2
1Y :	137.79%
5Y :	-56.34%
EPS(TTM): :	-1.37
Shares O/S :	88.26 M
Market cap :	323.04 M

What is the share price of Personalis Inc today?

Personalis Inc (PSNL) share price as of April 1, 2025, is $3.59. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Personalis Inc?

Yes, Indian Investors can invest in the Personalis Inc (PSNL) Share by opening an international trading account with Angel One.

How can I purchase Personalis Inc shares in India?

Purchasing Personalis Inc (PSNL) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Personalis Inc (PSNL) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Personalis Inc?

Yes, you can purchase fractional shares of Personalis Inc (PSNL) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Personalis Inc?

The market capitalization of Personalis Inc on April 1, 2025, is $316.87 M.

In which sector Personalis Inc belongs?

Personalis Inc operates in the Healthcare sector, specifically in the Diagnostics & Research industry.

What documents are required to invest in Personalis Inc stocks?

In order to invest in Personalis Inc (PSNL) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.